Xilio To Present Vilastobart Data In MSS CRC At ASCO GI Symposium

Xilio Therapeutics, Inc. is a clinical-stage biotech company focused on tumor-activated immuno-oncology therapies. The firm has announced their plans to share initial findings from its Phase 2 trial of vilastobart (XTX101) at the upcoming ASCO Gastrointestinal (ASCO GI) Cancers Symposium in San Francisco, California, taking place from January 23-25, 2025. Vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, is being studied in combination with atezolizumab (Tecentriq®) for treating metastatic microsatellite stable colorectal cancer (MSS CRC). 

“We are encouraged by the early evidence of responses in patients with cold tumors, including MSS colorectal cancer, reported for the combination of vilastobart and atezolizumab in Phase 1C dose escalation earlier this year, and we look forward to sharing initial Phase 2 data for the combination in MSS CRC at ASCO GI in January. In addition, the preliminary Phase 1 data we reported today for XTX301, our tumor-activated IL-12, highlight its promising clinical profile, including no dose-limiting toxicities reported to date and consistent interferon gamma signaling observed throughout treatment cycles,” said Katarina Luptakova, M.D., chief medical officer of Xilio.

Presentation Details

The data presentation, titled Phase 1/2 study of XTX101, a tumour-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with advanced solid tumors and in MSS CRC, is scheduled for:

• Date: Saturday, January 25, 2025

• Session: Poster Session C - Cancers of the Colon, Rectum, and Anus

• Time: 7:00 AM to 7:55 AM PST

• Location: Moscone West, San Francisco, CA

• Abstract Number: 206

In addition to this announcement, Xilio also shared preliminary Phase 1 dose escalation data for XTX301, its investigational tumour-activated IL-12 therapy. These updates underscore Xilio’s commitment to advancing innovative treatments for people living with cancer.